In colon cancer, normal colon tissue and blood cells have altered telomere lengths

2015 ◽  
Vol 111 (7) ◽  
pp. 899-904 ◽  
Author(s):  
Cristina Valls-Bautista ◽  
Carme Piñol-Felis ◽  
Josep M. Reñé-Espinet ◽  
Juan Buenestado-García ◽  
Joan Viñas-Salas
Keyword(s):  
Colon Cancer ◽  
Blood Cells ◽  
Normal Colon ◽  
Colon Tissue ◽  
Normal Colon Tissue

BNIP3L (Nix) expression in colon cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15097-e15097
Author(s):  
J. E. Littlejohn ◽  
D. Jupiter ◽  
X. Cao ◽  
L. Zhang ◽  
M. Shabahang ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Human Colon ◽  
Mrna Levels ◽  
Normal Colon ◽  
Colon Tissue ◽  
Human Colon Cancer ◽  
Variable Expression ◽  
Colon Tumors ◽  
Normal Colon Tissue ◽  
Protein Levels

e15097 Background: Microenvironmental adaptation to hypoxic conditions is critical for a cell to survive in a growing solid tumor. BNIP3L (Nix) mediates apoptosis during hypoxia in cancer cell lines, and Nix knockdown promotes tumor growth in-vivo through decreased apoptosis and increased proliferation, suggesting a means by which cells can adapt. Little is known specifically about Nix expression and its importance in human colon cancer. To gain insight into expression of this gene in colon tumors, the present study analyzed mRNA microarray data from 227 colon tumors and 22 normal colon tissue samples and queried differential expression of Nix. These results were compared to the protein levels present in human colon tumors. Methods: mRNA expression of 227 human colon tumors (made available by the Expression Project for Oncology (expO)) and 22 normal colon samples (retrieved from the Gene Expression Omnibus (GEO)) was analyzed. These samples were hybridized to the Affymetrix GeneChip Human Genome U133 Plus 2.0 Array, assaying 17,726 NCBI Entrez genes. Immunohistochemistry was performed on human tissue microarray CO701 (US Biomax, Inc.) containing 62 tumor samples. Results: Nix mRNA levels were shown to increase from normal to cancer (log-fold change of 0.961, Benjamini-Hochberg FDR adjusted p < 0.001). IHC demonstrated variable levels of Nix present in colon tumors: 38/62 (61.3%) of tumors stained positive for Nix while 24/62 (38.7%) were negative. Conclusions: We have shown that mRNA levels of Nix are upregulated in the transition from normal colon tissue to cancer but that protein levels in tumors demonstrate variable expression. This suggests that silencing of Nix occurs at various stages of tumorigenic progression and results in isolated populations of cells within a growing tumor that are uniquely resistant to apoptosis. Better understanding of Nix in the context of a growing colon tumor is needed and could lead to development of more successful therapeutics. No significant financial relationships to disclose.

Cold atmospheric plasma treatment inhibits growth in colorectal cancer cells

2018 ◽  
Vol 400 (1) ◽  
pp. 111-122 ◽  
Author(s):  
Christin Schneider ◽  
Stephanie Arndt ◽  
Julia L. Zimmermann ◽  
Yangfang Li ◽  
Sigrid Karrer ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Plasma Treatment ◽  
Cancer Cells ◽  
Ex Vivo ◽  
Atmospheric Plasma ◽  
Normal Colon ◽  
Colon Tissue ◽  
Cold Atmospheric Plasma ◽  
Colorectal Cancer Cells

AbstractPlasma oncology is a relatively new field of research. Recent developments have indicated that cold atmospheric plasma (CAP) technology is an interesting new therapeutic approach to cancer treatment. In this study, p53 wildtype (LoVo) and human p53 mutated (HT29 and SW480) colorectal cancer cells were treated with the miniFlatPlaSter – a device particularly developed for the treatment of tumor cells – that uses the Surface Micro Discharge (SMD) technology for plasma production in air. The present study analyzed the effects of plasma on colorectal cancer cellsin vitroand on normal colon tissueex vivo. Plasma treatment had strong effects on colon cancer cells, such as inhibition of cell proliferation, induction of cell death and modulation of p21 expression. In contrast, CAP treatment of murine colon tissueex vivofor up to 2 min did not show any toxic effect on normal colon cells compared to H2O2positive control. In summary, these results suggest that the miniFlatPlaSter plasma device is able to kill colorectal cancer cells independent of their p53 mutation status. Thus, this device presents a promising new approach in colon cancer therapy.

scholarly journals Genotype-Based Gene Expression in Colon Tissue—Prediction Accuracy and Relationship with the Prognosis of Colorectal Cancer Patients

2020 ◽  
Vol 21 (21) ◽  
pp. 8150
Author(s):  
Heike Deutelmoser ◽  
Justo Lorenzo Bermejo ◽  
Axel Benner ◽  
Korbinian Weigl ◽  
Hanla A. Park ◽  
...  
Keyword(s):  
Gene Expression ◽  
Colorectal Cancer ◽  
Prediction Accuracy ◽  
Inverse Association ◽  
Normal Colon ◽  
Colon Tissue ◽  
Normal Colon Tissue ◽  
Study Population ◽  
The Uk ◽  
Colorectal Cancer Patients

Colorectal cancer (CRC) survival has environmental and inherited components. The expression of specific genes can be inferred based on individual genotypes—so called expression quantitative trait loci. In this study, we used the PrediXcan method to predict gene expression in normal colon tissue using individual genotype data from 91 CRC patients and examined the correlation ρ between predicted and measured gene expression levels. Out of 5434 predicted genes, 58% showed a negative ρ value and only 16% presented a ρ higher than 0.10. We subsequently investigated the association between genotype-based gene expression in colon tissue for genes with ρ > 0.10 and survival of 4436 CRC patients. We identified an inverse association between the predicted expression of ARID3B and CRC-specific survival for patients with a body mass index greater than or equal to 30 kg/m2 (HR (hazard ratio) = 0.66 for an expression higher vs. lower than the median, p = 0.005). This association was validated using genotype and clinical data from the UK Biobank (HR = 0.74, p = 0.04). In addition to the identification of ARID3B expression in normal colon tissue as a candidate prognostic biomarker for obese CRC patients, our study illustrates the challenges of genotype-based prediction of gene expression, and the advantage of reassessing the prediction accuracy in a subset of the study population using measured gene expression data.

Immunihistochemical detection of galNAc-T6 to predict survival in patients with colon cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e14682-e14682
Author(s):  
Luis Ubillos ◽  
Mariela Rondan ◽  
Edgardo Berriel ◽  
Daniel Mazal ◽  
Enrique Barrios ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Prognostic Marker ◽  
Cell Lines ◽  
Initial Step ◽  
Cancer Tissue ◽  
Normal Colon ◽  
Colon Tissue ◽  
Tissue Samples ◽  
Independent Prognostic Marker ◽  
Colon Cell

e14682 Background: Alterations in the O-glycosylation is one of the most common changes during colon carcinogenesis, which leads to the expression of short O-glycan antigens (Tn, sialyl-Tn, Tk, and core 6). These structures are associated with malignant behavior being actively investigated as targets for immunotherapy. The enzymes of GalNAc-T family regulate the initial step in mucins O-glycosylation and could be responsible for the altered glycosylation observed in cancer. The aim of this work was to evaluate the expression of GalNAc-T6 in colon cancer, and to determine its role as prognostic marker. Methods: We evaluated GalNAc-T6 expression in colon cell lines by immunocytochemistry, and in colon cancer tissue samples by immunohistochemistry using the monoclonal antibody T6.3 developed by us (Berois et al. J Histochem Cytochem. 2006). We analyzed 103 colon cancer samples and 10 normal colon tissues. Results: We found that GalNAc-T6 (usually expressed in normal placenta, trachea, pancreas and brain) is detected in colon cancer cell lines. GalNAc-T6 was also detected by immunohistochemistry in 50.5% of samples with cancer and no expression was found in normal colon tissue. The staining pattern was predominantly cytoplasmic. Multivariate analysis showed that GalNAc-T6 expression is an independent prognostic marker predicting improved survival in patients with positive tumors (p 0.014). Conclusions: GalNAc-T6 could be a new independent prognostic marker to predict better outcome in colon cancer patients.

scholarly journals DNA demethylation in normal colon tissue predicts predisposition to multiple cancers

Oncogene ◽  
2012 ◽  
Vol 31 (48) ◽  
pp. 5029-5037 ◽  
Author(s):  
H Kamiyama ◽  
K Suzuki ◽  
T Maeda ◽  
K Koizumi ◽  
Y Miyaki ◽  
...  
Keyword(s):  
Dna Demethylation ◽  
Normal Colon ◽  
Colon Tissue ◽  
Normal Colon Tissue ◽  
Multiple Cancers

scholarly journals Extensive quantitative remodeling of the proteome between normal colon tissue and adenocarcinoma

2012 ◽  
Vol 8 (1) ◽  
pp. 611 ◽  
Author(s):  
Jacek R Wiśniewski ◽  
Paweł Ostasiewicz ◽  
Kamila Duś ◽  
Dorota F Zielińska ◽  
Florian Gnad ◽  
...  
Keyword(s):  
Normal Colon ◽  
Colon Tissue ◽  
Normal Colon Tissue
Sign in / Sign up

Export Citation Format

Share Document